FDA

Expert Insights

The Disconnect with Diabetic Foot Ulcers

12/23/2021

Kazem Kazempour

In this video, Kazem Kazempour , PhD, explains the disconnect between the FDA's definition of wound healing and the reality of DFUs.

In this video, Kazem...

12/23/2021

Wounds

Guest Editorial

When an Opportunity Knocked, the Wound Care Community Responded

06/03/2021

Vickie R. Driver, DPM, MS, FACFAS

Lisa Gould, MD, PhD, FACS

Peggy Dotson, RN, BS

The new Wound Care Collaborative Community is discussed.

The new Wound Care Collaborative...

06/03/2021

Wound Management & Prevention

FDA Alerts

FDA Approves Relugolix for Advanced Prostate Cancer

12/18/2020

Journal of Clinical Pathways

News

Dapagliflozin Labeling for Heart Failure With Reduced Ejection Fraction Applicable in US Clinical Practice

12/03/2020

Journal of Clinical Pathways

News

Cost-Benefit Analysis Shows Difference in Price, Clinical Benefit of Cancer Drugs in US, Europe

05/26/2020

A cost-benefit analysis published in The Lancet Oncology (May 2020;21[5]:664-670) compared the prices and clinical benefit of cancer drugs in the US vs Europe. Both the US and European countries are faced with the...

A...

05/26/2020

Journal of Clinical Pathways

Counterpoint

To Increase Innovation and Make Drugs More Affordable, Deregulate

10/27/2015

David R. Henderson, PhD

Charles L. Hooper, MS

Are there ways to make drugs more affordable without reducing the incentive to innovate? Dr. Owens makes two principal claims with which we agree. Any dialogue about the rising cost of cancer drugs must, as the...

Are...

10/27/2015

Journal of Clinical Pathways